PUBLISHER: 360iResearch | PRODUCT CODE: 2092303

PUBLISHER: 360iResearch | PRODUCT CODE: 2092303

Anthelmintic Drugs Market - Global Forecast 2026-2032

PUBLISHED: July 16, 2026

PAGES: 197 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Anthelmintic Drugs Market is projected to grow by USD 6.74 billion at a CAGR of 8.28% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 3.86 billion
Estimated Year [2026]	USD 4.17 billion
Forecast Year [2032]	USD 6.74 billion
CAGR (%)	8.28%

Anthelmintic drugs are essential anti-parasitic medicines used to prevent and treat helminth infections caused by nematodes, cestodes, and trematodes in humans and animals. Their role spans public health, livestock productivity, companion animal care, and food security, particularly in regions where soil-transmitted helminths, schistosomiasis, lymphatic filariasis, and gastrointestinal worm burdens remain persistent. Demand dynamics are shaped by national deworming programs, veterinary parasite-control protocols, antimicrobial and antiparasitic stewardship, rising companion animal ownership, and the need to protect agricultural output from productivity losses linked to parasitic infection. The landscape is also influenced by drug-resistance surveillance, combination therapy research, improved diagnostics, and policies supporting preventive chemotherapy in endemic populations. As governments, healthcare providers, veterinarians, and animal health stakeholders prioritize integrated parasite management, anthelmintic drugs continue to occupy a strategic position across human medicine, veterinary medicine, and One Health initiatives.

Transformative Shifts in the Anthelmintic Drugs Landscape

The anthelmintic drugs landscape is undergoing a shift from routine treatment models toward evidence-guided parasite control. In human health, mass drug administration programs continue to support disease control in endemic settings, while stronger pharmacovigilance and monitoring are improving treatment quality and safety. In animal health, livestock producers are increasingly adopting targeted selective treatment, fecal egg count monitoring, pasture management, and rotational strategies to reduce unnecessary exposure and slow resistance development. Regulatory authorities are strengthening quality standards for antiparasitic medicines, and procurement systems are placing greater emphasis on reliable supply, affordability, and program continuity. Innovation is also moving beyond conventional formulations toward improved palatability, fixed-dose combinations, extended-release delivery, and species-specific dosing formats. These transformative shifts are aligning anthelmintic use with precision health, sustainability, and long-term parasite-resistance management.

Cumulative Impact of Artificial Intelligence on Anthelmintic Drugs

Artificial intelligence is becoming a practical enabler across the anthelmintic drugs value chain, particularly in drug discovery, resistance monitoring, pharmacovigilance, and supply optimization. AI-supported molecular screening can help identify promising antiparasitic compounds and repurposing opportunities by analyzing biological pathways, parasite genomics, and structure-activity relationships. In field applications, machine learning models can support risk mapping for helminth transmission by combining climate, sanitation, livestock movement, land use, and treatment-history data. AI-enabled image analysis is also improving the efficiency of parasite egg detection in fecal diagnostics, supporting more targeted treatment decisions in veterinary and human health settings. Across supply chains, predictive analytics can help public health agencies and animal health distributors reduce stockouts, optimize inventory placement, and align procurement with seasonal parasite pressure. While AI does not replace laboratory validation or clinical evidence, it strengthens decision-making and accelerates the movement toward data-driven parasite control.

Key Regional Insights for Anthelmintic Drugs

Asia-Pacific remains a high-priority region for anthelmintic drugs due to a large population base, extensive livestock production, tropical and subtropical transmission conditions, and ongoing public health programs targeting soil-transmitted helminths and other neglected tropical diseases. Countries across the region combine school-based deworming, veterinary parasite management, and aquaculture-related health monitoring with improving diagnostic capacity. North America is characterized by strong companion animal care, advanced veterinary diagnostics, regulated livestock production, and high emphasis on parasite prevention protocols, with treatment decisions increasingly supported by surveillance and stewardship practices. Latin America faces diverse helminth burdens linked to rural livelihoods, climate variability, and livestock systems, while public and veterinary health efforts focus on access, education, and integrated parasite management. Europe shows strong regulatory oversight, established veterinary prescribing practices, and rising attention to anthelmintic resistance, especially in grazing livestock and equine health. The Middle East presents a mixed profile shaped by livestock trade, arid and semi-arid environments, migrant workforce health needs, and expanding veterinary infrastructure. Africa carries a substantial burden of helminth-related disease in both humans and animals, making access to quality-assured anthelmintics, mass treatment campaigns, sanitation improvements, and livestock productivity programs central to regional priorities.

Key Group Insights for Anthelmintic Drugs

ASEAN countries are important to the anthelmintic drugs landscape because tropical climate patterns, dense rural populations, smallholder farming, and public deworming initiatives support sustained attention to helminth control across both human and animal health. The GCC region emphasizes regulated healthcare delivery, livestock import management, camel and small-ruminant health, and preventive veterinary services, with parasite control linked to biosecurity and food supply resilience. The European Union reflects a mature regulatory and stewardship environment where veterinary antiparasitic use is shaped by prescribing controls, residue limits, environmental considerations, and growing resistance surveillance. BRICS economies combine large populations, major livestock sectors, and varying burdens of endemic parasitic disease, creating strong policy relevance for affordable medicines, domestic production capacity, and public health treatment programs. G7 countries generally show advanced research infrastructure, high veterinary care standards, and strong quality assurance, with emphasis on diagnostics, evidence-based prescribing, and innovation in human and animal antiparasitic therapies. NATO member countries overlap significantly with advanced healthcare and veterinary systems, where medical readiness, food supply security, zoonotic risk management, and resilient pharmaceutical supply chains contribute to the strategic relevance of anthelmintic access and oversight.

Key Country Insights for Anthelmintic Drugs

The United States demonstrates strong demand for anthelmintic drugs across companion animal care, livestock production, equine health, and regulated public health channels, with emphasis on prescription oversight, parasite diagnostics, and resistance-aware treatment. Canada reflects similar priorities, supported by veterinary stewardship, livestock health management, and companion animal preventive care, while Mexico combines companion animal growth, livestock needs, and public health relevance in rural and peri-urban settings. Brazil is a major animal health environment where cattle, sheep, companion animals, and tropical parasite pressures make integrated parasite control important, while the United Kingdom, Germany, France, Italy, and Spain are shaped by stringent regulatory systems, established veterinary services, grazing livestock management, and increasing concern over responsible anthelmintic use. Russia's large geography, livestock base, and varied climatic zones create broad parasite-control needs across animal health and public health contexts. China and India are central to global anthelmintic relevance due to large populations, significant livestock sectors, ongoing deworming initiatives, and expanding pharmaceutical manufacturing and healthcare access. Japan and South Korea show advanced veterinary care, regulated pharmaceutical quality, and strong companion animal health adoption, while Australia places particular emphasis on livestock parasite resistance management, grazing systems, and evidence-based worm control strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resistance stewardship by supporting diagnostics-led treatment, fecal egg count monitoring, and education on appropriate dosing and rotation strategies. Investment in quality-assured manufacturing, stable supply chains, and pharmacovigilance is essential to maintain trust across public health and veterinary channels. Product development should focus on improved adherence through palatable formulations, fixed-dose combinations where clinically appropriate, weight-appropriate dosing, and delivery formats suitable for field conditions. Stakeholders should strengthen collaboration with public health agencies, veterinarians, livestock producers, and academic institutions to improve surveillance for anthelmintic resistance and treatment outcomes. Digital tools, including AI-enabled risk mapping and diagnostic support, should be adopted carefully with validation against field data. Organizations should also align with One Health principles by considering human health, animal health, environmental exposure, and food security together when designing parasite-control strategies.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified and publicly available sources, including public health guidelines, regulatory frameworks, veterinary medicine references, disease-control program documentation, peer-reviewed scientific literature, and recognized One Health and neglected tropical disease resources. The analysis synthesizes evidence on helminth disease burden, anthelmintic use patterns, resistance concerns, veterinary applications, regulatory priorities, regional health infrastructure, and technology adoption. Insights are cross-validated across human health, animal health, and agricultural contexts to avoid reliance on a single data stream. The methodology excludes market sizing, revenue estimation, share calculation, and forecasting, focusing instead on qualitative, evidence-backed interpretation of structural drivers, policy relevance, regional dynamics, and operational priorities in the anthelmintic drugs landscape.

Conclusion

Anthelmintic drugs remain indispensable to global health, veterinary care, livestock productivity, and food security. The sector is evolving through stronger stewardship, better diagnostics, improved formulations, resistance monitoring, and the gradual integration of artificial intelligence into discovery, surveillance, and supply planning. Regional needs vary considerably, from mass deworming and access priorities in endemic settings to diagnostics-led prescribing and resistance management in mature veterinary systems. Future progress will depend on responsible use, quality assurance, collaborative surveillance, and One Health coordination that connects human medicine, animal health, agriculture, and environmental protection. Organizations that combine scientific rigor with practical field implementation will be best positioned to support sustainable parasite control and long-term treatment effectiveness.

Product Code: MRR-FB6C9E792F81

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anthelmintic Drugs Market, by Drug Class

7.1. Introduction
7.2. Benzimidazoles
7.3. Imidazothiazoles And Tetrahydropyrimidines
7.4. Macrocyclic Lactones

8. Anthelmintic Drugs Market, by Animal Type

8.1. Introduction
8.2. Companion Animals
- 8.2.1. Cats
- 8.2.2. Dogs
8.3. Food Producing Animals
- 8.3.1. Cattle
- 8.3.2. Poultry
- 8.3.3. Sheep And Goat
- 8.3.4. Swine
8.4. Human
- 8.4.1. Adults
- 8.4.2. Pediatric

9. Anthelmintic Drugs Market, by Route Of Administration

9.1. Introduction
9.2. Oral
9.3. Parenteral
9.4. Topical

10. Anthelmintic Drugs Market, by Sales Channel

10.1. Introduction
10.2. Online
10.3. Offline

11. Anthelmintic Drugs Market, by Application

11.1. Introduction
11.2. Human Health
11.3. Veterinary Health
11.4. Poultry
11.5. Aquaculture

12. Anthelmintic Drugs Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Anthelmintic Drugs Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Anthelmintic Drugs Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Aden Healthcare
16.2. Anikem Laboratories
16.3. Bayer AG
16.4. Boehringer Ingelheim International GmbH
16.5. Ceva Sante Animale
16.6. Cipla Limited
16.7. Dechra Pharmaceuticals PLC
16.8. Dr.Reddys Laboratories Inc.
16.9. Edenbridge Pharmaceuticals LLC
16.10. GlaxoSmithKline PLC
16.11. Green Cross Remedies
16.12. Healthy Life Pharma Private Limited
16.13. Johnson & Johnson Services, Inc.
16.14. Kosher Pharmaceuticals
16.15. Lineage Therapeutics Inc
16.16. Lupin Limited
16.17. Mankind Pharma Ltd.
16.18. McKesson Corporation
16.19. Merck & Co., Inc.
16.20. Norbrook Laboratories Limited
16.21. Novartis AG
16.22. Sankur Pharmaceuticals Pvt. Ltd
16.23. Takeda Pharmaceutical Company Limited
16.24. Virbac S.A.
16.25. Weefsel Pharma